The trade-off is a higher incidence of gastrointestinal side effects
In a third study, Julio Rosenstock, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues found that the mean HbA1c reductions were significantly greater with cagrilintide-semaglutide (2.4 mg each and 1.0 mg each: 2.33 and 2.10 percent, respectively) versus placebo (0.66 percent) at week 40 in 274 adults with type 2 diabetes using basal insulin
The validation dataset contains peptide identifiers (pep_ID), amino acid sequences, experimentally determined EC50 values in picomolar units (pM) for GCGR, GLP1R, and GIPR receptors, corresponding log-transformed EC50 values, and source publications
Dose and timing should be set against a confirmed deficiency, not by how you feel on any given week